Quest Diagnostics' partnership deal with a state-of-the-art French company is showing signs of paying off.
This year, organizers are holding the conference from July 20 to 25 in Melbourne, Australia. It has already been the site of some encouraging research announcements. We've highlighted one in this week's FierceDiagnostics, about a biomarker that might help spot patients who would respond best to a promising new HIV vaccine.
We all know the life sciences industry produces plenty of hype about new diagnostic advances, cutting-edge treatments and lifesaving surgeries. Many are profoundly amazing and life-changing inventions that have saved countless lives. But the truth is that much of patient diagnosis and care remains guesswork, trial, error and hope. Read more >>
POPULAR COMMENT THREADS
Revenue isn't yet growing fast enough for cancer diagnostics darling Foundation Medicine, making the recent New York State Department of Health approval of the Massachusetts company's two initial cancer tests all the more significant.
This summer, venture investment trends have given the medical diagnostics industry reason for at least a little optimism.
California's Epic Sciences nailed down $30 million in new financing it plans to use to commercialize tests that can detect circulating tumor cells during a patient's treatment, allowing for a more personalized cancer treatment as the disease evolves.
Japanese tech giant Konica Minolta sealed an agreement with a New Jersey diagnostics outfit to develop a test that can rapidly detect early cardiac muscle tissue damage after heart attacks strike.
Even as the diagnostics industry continues to pursue more sophisticated approaches to cancer testing, a group from the U.K. has come up with a simple blood test that could generate much more bang for the buck.
Qiagen aims to develop new tests to target blood cancer patients who would benefit most from a particular treatment that hits a specific gene mutation. The plan could lead to new companion diagnostic tests for related drugs now under development.
From Our Sister Sites
Oraya Therapeutics, the developer of a low energy X-ray beam that can safely deliver radiation therapy to the into the eye, is expanding its presence in Europe. The 20-minute one-time procedure is designed to reduce the need for anti-vascular endothelial growth factor injections in patients with wet age-related macular degeneration.
Gilead has picked up the exclusive rights to develop a set of HIV-neutralizing antibodies discovered at Theraclone in collaboration with the International AIDS Vaccine Initiative and The Scripps Research Institute. Seattle-based Theraclone, which used its tech platform I-STAR in the project, picked up an unspecified set of milestones and an upfront payment in the deal.